Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?

Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is applying the appropriate benefit/risk assessment for new drugs intended for this population.